-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
NCT05053230 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Uniondale
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: East Syracuse, Lake Success
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT05377996 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Comprehensive Outcomes for After Cancer Health
NCT05349227 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
NCT04751435 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn, Jamaica, New York, Richmond Hill
-
EXoPERT EMERALD Clinical Study
NCT07186296 ·
Phase: Not specified ·
Ages: 45 Years and older ·
Sex: All (male and female)
· New York: Albany, The Bronx, Wappingers Falls
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Integrated Cancer Repository for Cancer Research
NCT02012699 ·
Phase: Not specified ·
Ages: 19 Years to 110 Years ·
Sex: All (male and female)
· New York: Glens Falls, Utica
-
NYSCF Scientific Discovery Biobank
NCT06203106 ·
Phase: Not specified ·
Ages: 30 Days and older ·
Sex: All (male and female)
· New York: New York
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Mineola, New York
-
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· New York: Buffalo, Hempstead, Manhasset, New York
-
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT05799274 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: The Bronx
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, Rochester
-
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211 ·
Phase: Phase 2 ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· New York: Commack
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· New York: New York